- Home
- SQNS vs MRSN Comparison
SQNS vs MRSN Comparison
Compare SQNS & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- MRSN
- Stock Information
- Founded
- SQNS 2003
- MRSN 2001
- Country
- SQNS France
- MRSN United States
- Employees
- SQNS N/A
- MRSN N/A
- Industry
- SQNS Semiconductors
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- MRSN Health Care
- Exchange
- SQNS Nasdaq
- MRSN Nasdaq
- Market Cap
- SQNS 46.5M
- MRSN 40.7M
- IPO Year
- SQNS 2011
- MRSN 2017
- Fundamental
- Price
- SQNS $5.40
- MRSN $0.34
- Analyst Decision
- SQNS Strong Buy
- MRSN Strong Buy
- Analyst Count
- SQNS 1
- MRSN 5
- Target Price
- SQNS $7.50
- MRSN $5.75
- AVG Volume (30 Days)
- SQNS 10.1M
- MRSN 3.0M
- Earning Date
- SQNS 08-22-2025
- MRSN 08-12-2025
- Dividend Yield
- SQNS N/A
- MRSN N/A
- EPS Growth
- SQNS N/A
- MRSN N/A
- EPS
- SQNS 2.16
- MRSN N/A
- Revenue
- SQNS $38,858,000.00
- MRSN $34,006,000.00
- Revenue This Year
- SQNS N/A
- MRSN N/A
- Revenue Next Year
- SQNS $93.87
- MRSN $1.03
- P/E Ratio
- SQNS $2.08
- MRSN N/A
- Revenue Growth
- SQNS 40.06
- MRSN N/A
- 52 Week Low
- SQNS $0.95
- MRSN $0.26
- 52 Week High
- SQNS $5.83
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- SQNS 87.95
- MRSN 52.11
- Support Level
- SQNS $1.34
- MRSN $0.27
- Resistance Level
- SQNS $2.68
- MRSN $0.36
- Average True Range (ATR)
- SQNS 0.52
- MRSN 0.03
- MACD
- SQNS 0.29
- MRSN 0.01
- Stochastic Oscillator
- SQNS 76.77
- MRSN 65.92
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.